Windtree Therapeutics

Drug- and medtech developer Windtree Therapeutics (NSDQ:WINT) today said it appointed Diane Carman as senior VP and general counsel.

Carman will report directly to president and CEO Craig Fraser. She has more than two decades of experience working in life sciences and other highly regulated industries.

“We are delighted to welcome Diane to the Windtree team in her new role as general counsel,” Fraser said in a news release. “She is a talented and experienced executive with in-depth knowledge of pharmaceutical development companies and our clinical and business development operations. Her decades of legal and executive experience will be instrumental as we advance our multiple late-stage clinical candidates and grow the business.”

Prior to joining the company, Carman served as general counsel and secretary at Vitara Biomedical. She has also held numerous leadership roles at Helius Medical Technologies, Ablynx and Gamesa Technology.…

Drug- and medtech developer Windtree Therapeutics (NSDQ:WINT) today announced it named John Hamill as SVP and chief financial officer, replacing John Tattory, who is leaving to pursue other opportunities.

Hamill joins the company, which develops drug product and devices to treat acute cardiovascular and pulmonary disease, with 30 years in the pharma, biopharma and clinical research industries.

“We are delighted to have John join the Windtree team. He brings to us broad industry experience, having served as a seasoned financial executive and in a variety of senior roles for publicly traded companies,” said Windtree CEO Craig Fraser in a news release.

Most recently, he consulted for several life sciences companies including Trevana Inc., where he led a recent financing. He also saw Savient Pharmaceticals and PharmaNet through their own acquisitions, which brought in close to $400 million.

“I am very pleased to join Windtree, with i…

Windtree Therapeutics (OTCQB:WINT) announced today that it priced a public offering of common stock worth approximately $20 million.

The Warrington, Pa.-based company’s offering includes more than 2.7 million units of common stock at $7.25 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $7.975 per share, according to a news release.

Windtree’s warrants are exercisable for five years from the date of issuance and will be issued separately, with the company expecting gross proceeds of $20 million. Windtree intends to use the proceeds to advance its study of the KL4 surfactant for treating COVID-19-related lung injury, as well as for istaroxime Phase 2 start-up activities, the clinical development of Aerosurf for respiratory distress syndrome, pre-clinical studies of its oral SERCA2a activators for business development and other general purposes.

The company …